TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30391389

Group type: EXPERIMENTAL
Intervention: High-dose heparin (100 IU/kg body weight administered in divided doses)
Number of subjects: 1836

Group type: COMPARATOR
Intervention: Standard-dose heparin (50 IU/kg body weight)
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: High-dose heparin (100 IU/kg body weight)
Number of subjects: 1836
Study: 27509251

Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine (PrEP)
Number of subjects: 1200
Study: 25671951

Group type: EXPERIMENTAL
Intervention: Bolus injection of 30 mg/kg tranexamic acid
Number of subjects: 137

Group type: COMPARATOR
Intervention: Continuous infusion of tranexamic acid
Number of subjects: 137
Study: 22742439

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTI); details on dosage and duration not specified.
Number of subjects: 0
Study: 20231034

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 2332

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 2332
Study: 18166122

Group type: EXPERIMENTAL
Intervention: Relaxing Yoga plus Touch (RYT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Relaxing Yoga (RY)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both RY and RYT
Number of subjects: 40
Study: 15894479

Group type: EXPERIMENTAL
Intervention: Inhaled HFA beclomethasone (Ventolair)
Number of subjects: 11
Study: 12515670

Group type: EXPERIMENTAL
Intervention: rhGH small dose (0.3 IU.kg(‐1).d(‐1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rhGH large dose (0.6 IU.kg(‐1).d(‐1))
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 36
Study: 9488531

Group type: EXPERIMENTAL
Intervention: Glutamine dipeptide-enriched total parenteral nutrition (TPN)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (1.5 g of amino acids kg(‐1) day(‐1))
Number of subjects: 28
Study: 7999488

Group type: EXPERIMENTAL
Intervention: Midazolam 0.06 mg kg‐1 i.m.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg kg‐1 orally
Number of subjects: 48

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 48
Study: 2904310

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29744721

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 44

Group type: COMPARATOR
Intervention: Biodentine
Number of subjects: 44
Study: 28324049

Group type: EXPERIMENTAL
Intervention: 8-week intensive metabolic intervention
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 16-week intensive metabolic intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard diabetes care (control)
Number of subjects: 83
Study: 26436473

Group type: EXPERIMENTAL
Intervention: 1 g of intravenous acetaminophen every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: 1 g of intravenous acetaminophen
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 24223219

Group type: EXPERIMENTAL
Intervention: Negative emotionally salient words
Number of subjects: 45

Group type: COMPARATOR
Intervention: Neutral words
Number of subjects: 45
Study: 21187525

Group type: EXPERIMENTAL
Intervention: Modified Jasper Jumper (JJ)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Delaire-type facemask
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 18358927

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 2 weeks for 6 weeks followed by 12 weeks of continued treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Tocilizumab in open-label extension phase
Number of subjects: 56
Study: 16343858

Group type: EXPERIMENTAL
Intervention: Teicoplanin 800 mg pre-operatively (Group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Teicoplanin 400 mg pre-operatively plus two doses of 200 mg 24 h apart (Group B)
Number of subjects: 47
Study: 12544006

Group type: EXPERIMENTAL
Intervention: Red wine (40 g of alcohol daily for 3 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beer (40 g of alcohol daily for 3 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spirits (Dutch gin) (40 g of alcohol daily for 3 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 11
Study: 10916812

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 7
Study: 8726169

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (other anti-platelet drugs and/or warfarin potassium)
Number of subjects: 102
Study: 8219631

Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Argon laser treatment
Number of subjects: 10
Study: 2874411

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 411

Group type: COMPARATOR
Intervention: No additional treatment (control)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with CMF
Number of subjects: 411
Study: 29734461

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 27058593

Group type: EXPERIMENTAL
Intervention: Full correction (FC) single vision lenses (n = 75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: +0.50D undercorrection (UC) single vision lenses (n = 75)
Number of subjects: 150
Study: 25948674

Group type: EXPERIMENTAL
Intervention: Topical saffron (Crocus sativus L) gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23620937

Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX-UE 10), treatment given once a week for 4 weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medication group with erkangning syrup, administered 3 times a day for 4 weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy control group, no intervention mentioned.
Number of subjects: 80
Study: 20814189

Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.03 mg/kg/day
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.06 mg/kg/day
Number of subjects: 133

Group type: COMPARATOR
Intervention: Growth hormone + Oxandrolone (Ox) / Placebo (Pl)
Number of subjects: 133
Study: 18360665

Group type: EXPERIMENTAL
Intervention: 1% dyclonine spraying anesthesia
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: FRILJET local cryoanesthesia and pulp vitality test agent
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 300
Study: 16840441

Group type: EXPERIMENTAL
Intervention: Presentation of screening information as frequencies (n = 83)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Presentation of screening information as percentages (n = 86)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Obstetricians
Number of subjects: 166
Study: 12920470

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (25 g every 4 hours, not exceeding 8 doses)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intravenous oxytocin (continuous infusion)
Number of subjects: 210
Study: 10832518

Group type: EXPERIMENTAL
Intervention: Visuospatial copy of tennis ball trajectory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referent group allowed to see the actual referent trajectory
Number of subjects: 0
Study: 9095079

Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Potassium
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Protein
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Fiber
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Total Fat
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Monounsaturated Fat
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Polyunsaturated Fat
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Carbohydrates
Number of subjects: 662
Study: 7939948

Group type: EXPERIMENTAL
Intervention: 300 mg mebendazole (locally produced)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 300 mg mebendazole (original)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 500 mg mebendazole (original)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole (original)
Number of subjects: 196
Study: 3780818

Group type: EXPERIMENTAL
Intervention: Theophylline plus slow release nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophylline plus placebo
Number of subjects: 12
Study: 28295204

Group type: EXPERIMENTAL
Intervention: Mothers given instructions on spatial thinking and guidance
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mothers asked to play as usual (Control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Instructed dyads (children)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control dyads (children)
Number of subjects: 41
Study: 27611039

Group type: EXPERIMENTAL
Intervention: 25 μg dexmedetomidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 μg dexmedetomidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 75 μg dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (bupivacaine 0.5% + normal saline)
Number of subjects: 60
Study: 25555183

Group type: EXPERIMENTAL
Intervention: 8-week stress management program (10 min diaphragmatic breathing and 15 min progressive muscle relaxation twice per day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 53
Study: 22104016

Group type: EXPERIMENTAL
Intervention: In-person nutrition education and supermarket point-of-purchase healthful shopping program
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care (no treatment)
Number of subjects: 153
Study: 20693886

Group type: EXPERIMENTAL
Intervention: C1‐esterase inhibitor (100 U/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18842789

Group type: EXPERIMENTAL
Intervention: 200 mg quercetin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg (‐)‐epicatechin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg epigallocatechin gallate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 16076683

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Whole study population (regardless of intervention)
Number of subjects: 32
Study: 12059865

Group type: EXPERIMENTAL
Intervention: Unoprostone 0.15%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10406443

Group type: EXPERIMENTAL
Intervention: Computer-tailored nutrition education
Number of subjects: 1309

Group type: COMPARATOR
Intervention: General written nutrition advice
Number of subjects: 1309
Study: 8768870

Group type: EXPERIMENTAL
Intervention: GH/IGF‐I treatment (0.34 mg GH twice daily and 5.0 mg IGF‐I twice daily)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: GH/IGF‐I treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 66
Study: 1555623

Group type: EXPERIMENTAL
Intervention: Enalapril (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 22
Study: 3908494

Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg, 1 tablet 3 times per day for 5 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Root-planing alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 11
Study: 31486700

Group type: EXPERIMENTAL
Intervention: 80 mg of fluvastatin daily for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 20
Study: 27990769

Group type: EXPERIMENTAL
Intervention: Brushing from the lingual aspect
Number of subjects: 46

Group type: COMPARATOR
Intervention: Brushing from the buccal aspect
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Comparison of brushing orders
Number of subjects: 46
Study: 27016644

Group type: EXPERIMENTAL
Intervention: LNG‐IUS 8
Number of subjects: 766

Group type: COMPARATOR
Intervention: ENG implant
Number of subjects: 766
Study: 24636948

Group type: EXPERIMENTAL
Intervention: Continuous dietetic support
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Specialized knee exercise program
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: No attention
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (diet and no attention)
Number of subjects: 192
Study: 22971985

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) - cooking activities once a week for 15 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no cooking activities)
Number of subjects: 38
Study: 20462664

Group type: EXPERIMENTAL
Intervention: 45 mg of ustekinumab
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: 90 mg of ustekinumab
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230
Study: 18573392

Group type: EXPERIMENTAL
Intervention: High-dose insulin therapy (5 mU/kg/min) with dextrose 20% to maintain blood glucose levels between 70 and 110 mg/dL (group II)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intraoperative intravenous insulin infusion, titrated to maintain blood glucose concentrations less than 180 mg/dL (group I)
Number of subjects: 52
Study: 16143197

Group type: EXPERIMENTAL
Intervention: Latanoprost intratympanic injection (once daily for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo intratympanic injection
Number of subjects: 0
Study: 11828277

Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional harvesting
Number of subjects: 144
Study: 10618936

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 1 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 2 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 4 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intra-articular saline (control)
Number of subjects: 86
Study: 7582326

Group type: EXPERIMENTAL
Intervention: Morphological filter for single sweep records of ERP
Number of subjects: 9
Study: 1951152

Group type: EXPERIMENTAL
Intervention: Intervention group (low-fat diet instruction)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 303
Study: 6406705

Group type: EXPERIMENTAL
Intervention: Amino acids alone (1.4 g/kg/day)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Amino acids (1.4 g/kg/day) plus 5% dextrose
Number of subjects: 93

Group type: COMPARATOR
Intervention: 5% dextrose alone
Number of subjects: 93
Study: 31044746

Group type: EXPERIMENTAL
Intervention: Group Explained (detailed explanation of the procedure)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Group Unexplained (brief explanation of the procedure)
Number of subjects: 184
Study: 29092028

Group type: EXPERIMENTAL
Intervention: Baseline Mental Component Summary (MCS) score
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Baseline Physical Component Summary (PCS) score
Number of subjects: 762
Study: 27102812

Group type: EXPERIMENTAL
Intervention: blended Cognitive Behavioural Therapy (bCBT) combining face-to-face and online sessions over 19-20 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: blended Cognitive Behavioural Therapy (bCBT)
Number of subjects: 0
Study: 24399768

Group type: EXPERIMENTAL
Intervention: Puerh tea extract capsule (333 mg Puerh tea extract) three times a day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 70
Study: 22771129

Group type: EXPERIMENTAL
Intervention: Adolescent/family dyads discussing advance directives
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adolescent/family dyads' thoughts about dying in pain
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adolescent/family dyads' thoughts about being off life support machines
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Families' knowledge of teens' preferences for timing of EOL conversations
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adolescents' desire to discuss EOL issues
Number of subjects: 48
Study: 21073130

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (primary conventional treatment alone)
Number of subjects: 48
Study: 17668232

Group type: EXPERIMENTAL
Intervention: 5,000 IU rHuEpo every second day for 14 days, followed by a single dose of 5,000 IU weekly for 10 weeks
Number of subjects: 8
Study: 15731394

Group type: EXPERIMENTAL
Intervention: ECW measurement in African Americans
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: ECW measurement in females
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: ECW measurement in males
Number of subjects: 1538
Study: 11970778

Group type: EXPERIMENTAL
Intervention: Priming with extreme speed ('cheetah')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming with extreme slowness ('turtle')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived comparability experimentally varied
Number of subjects: 0
Study: 9813955

Group type: EXPERIMENTAL
Intervention: Methylphenidate (fixed dose for at least 1 month)
Number of subjects: 29
Study: 8106759

Group type: EXPERIMENTAL
Intervention: Intranasal live cold-adapted (ca) influenza A vaccine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intramuscular trivalent inactivated (triv) influenza vaccine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 130
Study: 2759221

Group type: EXPERIMENTAL
Intervention: Exercise intervention (8 minute bicycle ride at 90% of predicted heart-rate)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control day (no exercise)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 86
Study: 1131627

Group type: EXPERIMENTAL
Intervention: Combination of primidone and phenytoin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Primidone alone
Number of subjects: 50
Study: 31891225

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help (GSH-I)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Objective adherence parameters (number of messages exchanged, days with a completed food diary, days spent per module)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Not completing the food diary in week 7
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Patients' body mass index
Number of subjects: 89
Study: 31059418

Group type: COMPARATOR
Intervention: 9 months of twice‐weekly isoniazid (9H)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 12 once‐weekly doses of isoniazid and rifapentine (3HP)
Number of subjects: 214
Study: 28733656

Group type: EXPERIMENTAL
Intervention: Glucocorticoid and cyclophosphamide (50-100 mg per day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Prednisone monotherapy (0.5-1.0 mg/kg.d, tapered gradually)
Number of subjects: 102
Study: 26513726

Group type: EXPERIMENTAL
Intervention: Substance use among men (89.4%) vs. women (55.2%)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Alcohol use among men vs. women
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cannabis use among men vs. women
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cocaine use among men vs. women
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Age at first consumption of cannabis
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Influence of number of substances used on age at onset of psychosis in women
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Influence of number of substances used on age at onset of psychosis in men
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Prediction of age at onset of psychosis
Number of subjects: 114
Study: 23032085

Group type: EXPERIMENTAL
Intervention: U-Cl(crea-urea)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: cP-Cl(EDTA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: U-Cl(EDTA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: eGFR(CysC)
Number of subjects: 12
Study: 21742284

Group type: EXPERIMENTAL
Intervention: Olive oil applied to abdominal skin area twice a day until the end of the study term
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no oil used)
Number of subjects: 0
Study: 19832737

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 70
Study: 16884439

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI) treatment for 12 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study: 15293587

Group type: EXPERIMENTAL
Intervention: Intensive care unit-based nursing screening intervention using the Discharge Planning Questionnaire (n = 47)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual discharge planning (n = 53)
Number of subjects: 100
Study: 11402106

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a, 44 microg three times weekly for 3 years
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a, 22 microg three times weekly for 3 years
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Combined interferon beta-1a groups
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study: 9230722

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM) 24 micrograms twice daily for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled placebo (PL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM) + oral prednisolone 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM) + systemic corticosteroid
Number of subjects: 12